BioMarin International Limited – FDA 483
BioMarin International Ltd.'s drug substance manufacturing facility in Ringaskiddy, Ireland, was cited for three observations. The inspection revealed inadequate investigation of deviations, specifically regarding bioburden excursions and the lack of proper corrective and preventive actions for sanitization. Additionally, microbial control of a manufacturing skid was found to be inadequate, with spore-forming bacteria identified in multiple lots, and there was no protocol to verify the effectiveness of sanitization solutions.
- Product type
- drugs
ID · a6c14a38-796a-49d1-b12e-03d5e5ad6540
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.